Company Profile · Healthcare

Medtronic PLC

MDT · US
Exchange
US
Country
USA
IPO date
Jan 13, 1978
Employees
95,000
Current Price
$79.34
Live · Jun 18, 2026
Fair Buy
≤ $65
Margin-of-safety entry
Baillie Growth Score
49/100
Weak
Intrinsic Value · Three-Tier Range Current price $79.34 Live · Within the fair intrinsic-value range

Composite valuation range · conservative $50–$60 / fair $60–$80 / optimistic $80–$100. At $79.34, Within the fair intrinsic-value range.

At publication $78 (May 25, 2026)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Market cap$100.32B
Revenue (TTM)$36.36B
EBITDA$10.08B
Profit margin13.2%
ROE9.93%
P/E (TTM)20.73
Forward P/E13.11
PEG1.54
EPS$3.77
Dividend yield3.49%
52-week range$73.31 – $104.70
Analyst target$98.00
Analyst rating3.8 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.